Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration
| Autor: | O. Cars, T. Salmonson, B. Wikström, A. A. Alarabi, B. G. Danielson |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Imipenem medicine.drug_class medicine.medical_treatment Antibiotics Cilastatin Imipenem Drug Combination Pharmacology Pharmacokinetics Internal medicine Hemofiltration polycyclic compounds medicine Humans Pharmacology (medical) Dosing Aged Cilastatin business.industry Imipenem/cilastatin Half-life Middle Aged Anti-Bacterial Agents Drug Combinations Infectious Diseases Endocrinology Injections Intravenous Kidney Failure Chronic bacteria Female lipids (amino acids peptides and proteins) business Half-Life medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 26:91-98 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/26.1.91 |
| Popis: | The pharmacokinetics of a single iv dose of imipenem/cilastatin (500/500 mg) were studied during and after intermittent haemofiltration (IHF) treatment in six patients with chronic renal failure. The elimination half-lives of imipenem and cilastatin during the IHF treatment were almost identical, 1.4 +/- 0.3 and 1.5 +/- 0.3 h, respectively. Accordingly, approximately 75% of the given dose was eliminated during a 3-h IHF session. However, there was a great difference between the elimination half-lives of the two drugs in the post-treatment period, 3.4 +/- 1.0 and 16 +/- 10 h for imipenem and cilastatin, respectively. The haemofiltration clearance of imipenem was 134 +/- 41 ml/min and that of cilastatin 109 +/- 8 ml/min. On the basis of our results, we suggest that a supplementary dose of imipenem/cilastatin (500/500 mg) should be given directly after the IHF treatment. This dose should be the starting dose for a period of 12-h dosing intervals until the next IHF procedure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|